Tocilizumab for COVID-19

1	
2	
3	Tocilizumab in patients admitted to hospital with
4	COVID-19 (RECOVERY): preliminary results of a
5	randomised, controlled, open-label, platform trial
6	
7	Running title: Tocilizumab for COVID-19
8	
9	RECOVERY Collaborative Group*
10	
11	
12	*The writing committee and trial steering committee are listed at the end of this
13	manuscript and a complete list of collaborators in the Randomised Evaluation of
14	COVID-19 Therapy (RECOVERY) trial is provided in the Supplementary Appendix.
15	
16	Correspondence to: Professor Peter W Horby and Professor Martin J Landray,
17	RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus,
18	Roosevelt Drive, Oxford OX3 7LF, United Kingdom.
19	Email: recoverytrial@ndph.ox.ac.uk
20	
21	
22	

Tocilizumab for COVID-19

23 SUMMARY

Background: Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin (IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We evaluated the safety and efficacy of tocilizumab in adult patients admitted to hospital with COVID-19 with evidence of both hypoxia and systemic inflammation.

28 **Methods:** This randomised, controlled, open-label, platform trial (Randomised Evaluation 29 of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in 30 patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia 31 (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic 32 inflammation (C-reactive protein [CRP] \geq 75 mg/L) were eligible for randomisation to usual 33 standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 34 mg to 800 mg (depending on weight) given intravenously. A second dose could be given 35 12 to 24 hours later if the patient's condition had not improved. The primary outcome was 36 28-day mortality, assessed in the intention-to-treat population. The trial is registered with 37 ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

Findings: Between 23 April 2020 and 24 January 2021, 4116 adults were included in the assessment of tocilizumab, including 562 (14%) patients receiving invasive mechanical ventilation, 1686 (41%) receiving non-invasive respiratory support, and 1868 (45%) receiving no respiratory support other than oxygen. Median CRP was 143 [IQR 107-204] mg/L and 3385 (82%) patients were receiving systemic corticosteroids at randomisation. Overall, 596 (29%) of the 2022 patients allocated tocilizumab and 694 (33%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0.86; 95% confidence

Tocilizumab for COVID-19

45	interval [CI] 0.77-0.96; p=0.007). Consistent results were seen in all pre-specified
46	subgroups of patients. In particular, a clear mortality benefit was seen in those receiving
47	systemic corticosteroids. Patients allocated to tocilizumab were more likely to be
48	discharged from hospital alive within 28 days (54% vs. 47%; rate ratio 1.22; 95% CI 1.12-
49	1.34; p<0.0001). Among those not receiving invasive mechanical ventilation at baseline,
50	patients allocated tocilizumab were less likely to reach the composite endpoint of invasive
51	mechanical ventilation or death (33% vs. 38%; risk ratio 0.85; 95% CI 0.78-0.93;
52	p=0·0005).

Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the level of respiratory support and were additional to the benefits of systemic corticosteroids.

Funding: UK Research and Innovation (Medical Research Council) and National Institute
of Health Research (Grant ref: MC_PC_19056).

59 Keywords: COVID-19, tocilizumab, clinical trial.

60

.

Tocilizumab for COVID-19

61 **INTRODUCTION**

The majority of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are either asymptomatic or result in only mild disease.¹ However, a substantial proportion of infected individuals develop a respiratory illness requiring hospital care, which can progress to critical illness with hypoxic respiratory failure requiring prolonged ventilatory support. Among COVID-19 patients admitted to UK hospitals in Spring 2020, the case fatality rate was over 26%, and was in excess of 37% in patients requiring invasive mechanical ventilation.²

69 Hypoxic respiratory failure in patients with COVID-19 is associated with evidence of 70 systemic inflammation, including release of pro-inflammatory cytokines, such as 71 interleukin (IL)-1, IL-6 and TNF α , and elevated levels of D-dimers, ferritin, and C-reactive 72 protein (CRP).^{3,4} The host immune response is thought to play a key role in driving an 73 acute inflammatory pneumonic process with diffuse alveolar damage, myeloid cell 74 infiltrates, and microvascular thrombosis.⁵ The beneficial effects of dexamethasone and 75 other corticosteroids in COVID-19 patients with hypoxic lung damage suggest that other, 76 more specific immunomodulatory agents may provide additional improvements in clinical 77 outcomes.^{6,7}

Tocilizumab is a recombinant humanised anti-IL-6 receptor monoclonal antibody that inhibits the binding of IL-6 to both membrane and soluble IL-6 receptors, blocking IL-6 signalling and reducing inflammation. Tocilizumab is licensed in the UK as an intravenous treatment for patients with rheumatoid arthritis and for people with chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome.

Tocilizumab for COVID-19

Randomised trials of tocilizumab in COVID-19 have so far shown mixed results for 28day mortality: six small trials reported no benefit while the somewhat larger REMAP-CAP
trial reported a benefit in patients requiring organ support.⁸⁻¹⁴ Here we report the results
of a large randomised controlled trial of tocilizumab in adult patients hospitalised with
severe COVID-19 characterised by hypoxia and significant inflammation.

88

89 METHODS

90 Study design and participants

91 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-92 initiated, individually randomised, controlled, open-label, platform trial to evaluate the 93 effects of potential treatments in patients hospitalised with COVID-19. Details of the trial 94 design and results for other possible treatments have been published previously.^{6,15-17} 95 The trial is being conducted in acute National Health Service (NHS) hospitals in the UK. 96 supported by the National Institute for Health Research Clinical Research Network. The 97 trial is coordinated by the Nuffield Department of Population Health at University of Oxford 98 (Oxford, UK), the trial sponsor. The trial is conducted in accordance with the principles of 99 the International Conference on Harmonisation–Good Clinical Practice guidelines and 100 approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and 101 the Cambridge East Research Ethics Committee (ref: 20/EE/0101). The protocol, 102 statistical analysis plan, and additional information are available on the study website 103 www.recoverytrial.net. This report is limited to adult patients. The randomised 104 assessment of tocilizumab in children under 18 years old is ongoing.

Tocilizumab for COVID-19

Patients admitted to hospital were eligible for the study if they had clinically suspected or laboratory confirmed SARS-CoV-2 infection and no medical history that might, in the opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial. Written informed consent was obtained from all patients, or their legal representative if they were too unwell or unable to provide consent.

110 Randomisation and masking

111 Data were collected at study entry using a web-based case report form that included 112 demographics and major comorbidities (appendix p 32). All eligible and consenting 113 patients received usual standard of care and underwent an initial (main) randomisation 114 comprising up to 3 parts in a factorial design (appendix p 29): part 1, no additional 115 treatment vs. either dexamethasone, lopinavir-ritonavir, hydroxychloroquine, 116 azithromycin, or colchicine; part 2, no additional treatment vs. either convalescent plasma 117 or REGN-COV2 (a combination of two monoclonal antibodies directed against SARS-118 CoV-2 spike protein); and part 3, no additional treatment vs. aspirin. Over time, treatment 119 arms were added to and removed from the protocol (appendix p 26), and not all 120 treatments were available at every hospital. Similarly, not all treatments were suitable for 121 some patients (e.g. due to comorbid conditions or concomitant medication). In any of 122 these cases, randomisation was between fewer arms.

Up to 21 days after the main randomisation and regardless of treatment allocation, RECOVERY trial participants with clinical evidence of progressive COVID-19 (defined as oxygen saturation <92% on room air or receiving oxygen therapy, and CRP ≥75 mg/L) could be considered for randomisation to tocilizumab vs. usual care alone. Baseline data

Tocilizumab for COVID-19

127 collected for this second randomisation included level of respiratory support, markers of 128 progressive COVID-19 (including oxygen saturation, CRP, ferritin, creatinine), suitability 129 for the study treatment, and treatment availability at the site (appendix p 34). For some 130 patients, tocilizumab was unavailable at the hospital at the time of enrolment or was 131 considered by the managing physician to be either definitely indicated or definitely 132 contraindicated. In such cases, the patients were not eligible for the tocilizumab 133 randomisation. Patients with known hypersensitivity to tocilizumab, evidence of active 134 tuberculosis infection or clear evidence of active bacterial, fungal, viral, or other infection 135 (besides COVID-19) were not eligible for randomisation to tocilizumab.

136 Patients who were eligible for randomisation to tocilizumab were assigned to either usual 137 standard of care or usual standard of care plus tocilizumab in a 1:1 ratio using web-based 138 simple (unstratified) randomisation with allocation concealed until after randomisation. 139 Patients allocated to tocilizumab were to receive tocilizumab as a single intravenous 140 infusion over 60 minutes. The dose of tocilizumab was determined by body weight (800 141 ma if weight >90kg; 600 ma if weight >65 and \leq 90 kg; 400 ma if weight >40 and \leq 65 kg; 142 and 8mg/kg if weight ≤40 kg). A second dose could be given 12 to 24 hours later if, in the 143 opinion of the attending clinician, the patient's condition had not improved. Allocated 144 treatment was prescribed by the managing doctor. Roche Products Ltd (UK) supported 145 the trial through provision of tocilizumab. Participants and local study staff were not 146 masked to the allocated treatment. The steering committee, investigators, and all others 147 involved in the trial were masked to the outcome data during the trial.

148

Tocilizumab for COVID-19

149 **Procedures**

150 A single online follow-up form was completed when participants were discharged, had 151 died or at 28 days after the initial randomisation, whichever occurred earliest (appendix p 152 36-41). Information was recorded on adherence to allocated study treatment, receipt of 153 other COVID-19 treatments, duration of admission, receipt of respiratory or renal support. 154 and vital status (including cause of death). In addition, routine healthcare and registry 155 data were obtained for the full follow-up period, including information on vital status (with 156 date and cause of death), discharge from hospital, receipt of respiratory support, or renal 157 replacement therapy.

158 Outcomes

159 Outcomes were assessed at 28 days after randomisation to tocilizumab vs. usual care 160 alone, with further analyses specified at 6 months. The primary outcome was all-cause 161 mortality. Secondary outcomes were time to discharge alive from hospital, and, among 162 patients not receiving invasive mechanical ventilation at randomisation, receipt of invasive 163 mechanical ventilation (including extra-corporeal membrane oxygenation) or death. 164 Prespecified subsidiary clinical outcomes were use of non-invasive respiratory support 165 (defined as high flow nasal oxygen, continuous positive airway pressure, or non-invasive 166 ventilation), time to successful cessation of invasive mechanical ventilation (defined as 167 cessation of invasive mechanical ventilation within, and survival to, 28 days), and use of 168 renal dialysis or haemofiltration. Prespecified safety outcomes included cause-specific 169 mortality and major cardiac arrhythmia. Information on suspected serious adverse 170 reactions was collected in an expedited fashion to comply with regulatory requirements.

Tocilizumab for COVID-19

171 Statistical Analysis

172 In accordance with the statistical analysis plan (version 2.1 appendix pp 93-117), an 173 intention-to-treat comparison was conducted between patients who entered the 174 randomised comparison of tocilizumab vs. usual care. For the primary outcome of 28-day 175 mortality, the log-rank observed minus expected statistic and its variance were used to 176 test the null hypothesis of equal survival curves (i.e., the log-rank test) and to calculate the one-step estimate of the average mortality rate ratio. We constructed Kaplan-Meier 177 178 survival curves to display cumulative mortality over the 28-day period. For this preliminary 179 report, information on the primary outcome is available for 92% of randomised patients. 180 Those patients who had not been followed for 28 days and were not known to have died 181 by the time of the data cut for this preliminary analysis (8 February 2021) were either 182 censored on 8 February 2021 or, if they had already been discharged alive, were right-183 censored for mortality at day 29 (that is, in the absence of any information to the contrary 184 they were assumed to have survived 28 days). [Note: This censoring rule will not be 185 necessary when all patients have completed the 28 day follow-up period on 25 February 186 2021.] We used the same method to analyse time to hospital discharge and successful 187 cessation of invasive mechanical ventilation, with patients who died in hospital right-188 censored on day 29. For the pre-specified composite secondary outcome of invasive 189 mechanical ventilation or death within 28 days (among those not receiving invasive 190 mechanical ventilation at randomisation) and the subsidiary clinical outcomes of receipt 191 of ventilation and receipt of haemodialysis or haemofiltration, the precise dates were not 192 available and so the risk ratio was estimated instead.

Tocilizumab for COVID-19

Prespecified analyses of the primary outcome were performed in subgroups defined by six characteristics at the time of randomisation: age, sex, ethnicity, level of respiratory support, days since symptom onset, and use of systemic corticosteroids (including dexamethasone). Observed effects within subgroup categories were compared using a chi-squared test for heterogeneity or trend, in accordance with the prespecified analysis plan.

Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values are 2-sided and are shown without adjustment for multiple testing. The full database is held by the study team which collected the data from study sites and performed the analyses at the Nuffield Department of Population Health, University of Oxford (Oxford, UK).

204 Prior to commencement of the randomisation to tocilizumab vs. usual care, the trial 205 steering committee determined that if 28-day mortality in the usual care group was 206 above 25% then recruitment of around 4000 patients to this comparison would provide 207 90% power at two-sided P=0.01 to detect a proportional reduction in 28-day mortality of 208 one-fifth. Consequently, Roche Products Ltd provided sufficient treatment for 2000 209 patients to receive tocilizumab. The trial steering committee, masked to the results, 210 closed recruitment to the tocilizumab comparison at the end of January 24, 2021 as 211 over 4000 patients had been randomised.

Analyses were performed using SAS version 9.4 and R version 3.4. The trial is registered
with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

214

Tocilizumab for COVID-19

215 Role of the funding source

Neither the funders of the study nor Roche Products Ltd had any role in study design, data collection, data analysis, data interpretation, or writing of the report. Roche Products Ltd supported the study through the supply of tocilizumab and reviewed the draft publication for factual accuracy relating to tocilizumab. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

222

223 **RESULTS**

224 Between 14 April 2020 and 24 January 2021, 4116 (19%) of 21550 patients enrolled into 225 the RECOVERY trial at one of the 131 sites in the UK participating in the tocilizumab 226 comparison were eligible for randomisation. 2022 patients were randomly allocated to 227 tocilizumab and 2094 were randomly allocated to usual care. The mean age of these participants was 63.6 years (SD 13.7). At randomisation, 562 (14%) patients were 228 229 receiving invasive mechanical ventilation, 1686 (41%) were receiving non-invasive 230 respiratory support (including high-flow nasal oxygen, continuous positive airway 231 pressure, and non-invasive ventilation), and 1868 (45%) were receiving no respiratory 232 support other than simple oxygen therapy (9 of these patients were reportedly not 233 receiving oxygen at randomisation) (table 1). Median CRP was 143 [IQR 107-204] mg/L. 234 82% of patients were reported to be receiving corticosteroids at randomisation (and 97% 235 of the patients enrolled since the announcement of the dexamethasone result from RECOVERY in June 2021). 236

Tocilizumab for COVID-19

237 The follow-up form was completed for 1602 (79%) of 2022 randomised patients in the 238 tocilizumab group and 1664 (79%) of 2094 patients in the usual care group. [Follow-up 239 forms are expected for >95% of participants by the time of the final analyses.] Among 240 patients with a completed follow-up form, 1333 (83%) allocated to tocilizumab and 44 241 (3%) of those allocated to usual care received at least one dose of tocilizumab (or 242 sarilumab, another IL-6 antagonist; figure 1; webtable 1), 461 (29%) patients in the 243 tocilizumab group and 10 (<1%) in the usual care group received more than 1 dose of 244 tocilizumab (or sarilumab). Use of other treatments for COVID-19 during the 28 days after 245 randomisation was similar among patients allocated tocilizumab and among those 246 allocated usual care (webtable 1).

Allocation to tocilizumab was associated with a significant reduction in the primary outcome of 28-day mortality compared with usual care alone (596 [29%] of 2022 patients in the tocilizumab group vs. 694 (33%) of 2094 patients in the usual care group; rate ratio 0.86; 95% confidence interval [CI], 0.77 to 0.96; p=0.007; figure 2a). In an exploratory analysis restricted to the 3858 (94%) patients with a positive SARS-CoV-2 test result, the result was similar (rate ratio 0.87, 95% CI 0.78 to 0.98; p=0.02).

Allocation to tocilizumab was associated with a greater probability of discharge from hospital alive within 28 days (54% vs. 47%; rate ratio 1.22, 95% CI 1.12 to 1.34, p<0.0001; figure 2b and table 2). Among those not on invasive mechanical ventilation at baseline, allocation to tocilizumab was associated with a reduction in the risk of progressing to the pre-specified composite secondary outcome of invasive mechanical ventilation or death when compare to usual care alone (33% vs. 38%, risk ratio 0.85, 95% CI 0.78 to 0.93, p=0.0005; table 2).

Tocilizumab for COVID-19

We observed similar results across all pre-specified sub-groups (figure 3 and webfigures 2 and 3), including the level of respiratory support at randomisation (figure 3). Given the number of hypothesis tests conducted, the suggestion of a larger proportional mortality reduction among those receiving a corticosteroid compared with those not [interaction p=0.01] may reflect the play of chance. An exploratory analysis showed that the effects of tocilizumab on 28-day mortality were similar for those randomised ≤ 2 or >2 days since hospitalisation (interaction p=0.86).

267 In pre-specified subsidiary analyses, we found no significant effect of tocilizumab on 268 subsequent receipt of non-invasive respiratory support or invasive mechanical ventilation 269 among those on no respiratory support at randomisation (table 2, webfigure 1). Nor was 270 there a significant effect on the rate of successful cessation of invasive mechanical 271 ventilation among those on invasive mechanical ventilation at randomisation. However, 272 allocation to tocilizumab reduced the use of haemodialysis or haemofiltration (5% vs. 7%, 273 risk ratio 0.75, 95% CI 0.59 to 0.96, p=0.02; table 2). Preliminary information on cause-274 specific mortality shows no evidence of excess deaths from other infections (webtable 2). 275 We observed no significant differences in the frequency of new cardiac arrhythmias 276 (webtable 3). There were three reports of serious adverse reactions believed to be related 277 to tocilizumab: one each of otitis externa, Staphylococcus aureus bacteraemia, and lung 278 abscess, all of which resolved with standard treatment.

279

Tocilizumab for COVID-19

281 **DISCUSSION**

282 The results of this large, randomised trial indicate that tocilizumab is an effective 283 treatment for hospitalised COVID-19 patients who have hypoxia and evidence of 284 inflammation (CRP \geq 75 mg/L). Treatment with tocilizumab improved survival and the 285 chances of discharge from hospital alive by 28 days, and reduced the chances of 286 progressing to require invasive mechanical ventilation. These benefits were consistent 287 across all patient groups studied, including those receiving invasive mechanical 288 ventilation, non-invasive respiratory support, or no respiratory support other than simple 289 oxygen. The benefits of tocilizumab were clearly seen among those also receiving 290 treatment with a systemic corticosteroid such as dexamethasone. There was also a 291 significant reduction in the need for haemodialysis or haemofiltration. Although we did not 292 see any effect on the duration of invasive mechanical ventilation, only 185 patients had 293 such ventilation successfully removed within the first 28 days, so power to detect any 294 benefit was low.

295 Since mid-2020, seven randomised controlled trials of tocilizumab for the treatment of 296 COVID-19 have reported. These include six small trials (fewer than 100 deaths in each) 297 and the somewhat larger REMAP-CAP trial, which recruited critically ill patients with 298 COVID-19, over 99% of whom required non-invasive respiratory support or invasive 299 mechanical ventilation.⁸⁻¹⁴ Taken together, these previous trials did not show a significant 300 mortality benefit for treatment with tocilizumab (death rate ratio 0.91, 95% CI 0.72-1.14, 301 figure 4). The RECOVERY trial contains over three times as many deaths as all the 302 previous trials combined. When all 8 trials are considered together, allocation to

Tocilizumab for COVID-19

tocilizumab is associated with a 13% proportional reduction in 28-day mortality (death
rate ratio 0.87, 95% CI 0.79-0.96, p=0.005, figure 4).

These benefits are in addition to those previously reported for corticosteroids, which is now usual standard of care for COVID-19 patients requiring treatment with oxygen.^{6,18} Our data suggest that in COVID-19 patients who are hypoxic and have evidence of systematic inflammation, treatment with a combination of a systemic corticosteroid plus tocilizumab would be expected to reduce mortality by about one-third for patients receiving simple oxygen and nearly one-half for those receiving invasive mechanical ventilation.

Previous trials have provided weak evidence that tocilizumab may shorten time to discharge or reduce progression to invasive mechanical ventilation or death.^{10,14} Our results show that in a broad spectrum of patients, tocilizumab increases the chances of being discharged alive within 28 days and reduces the chance of progression to receiving invasive mechanical ventilation. As with the mortality benefit, these effects are consistent regardless of the level of respiratory support at the time of enrolment.

Strengths of this trial included that it was randomised, had a large sample size, and included patients requiring various levels of respiratory support (from simple oxygen through to invasive mechanical ventilation). There are some limitations: For this preliminary report, information on the primary outcome is available for 92% of patients. This should increase to >99% by early March when all patients have passed the 28-day follow-up period. Following random assignment, 17% of patients in the tocilizumab group did not receive this treatment. The reasons for this were not recorded. The size of the

Tocilizumab for COVID-19

effects of tocilizumab reported in this paper are therefore an underestimate of the true effects of actually using the treatment. Hospital stay is very long for many of these patients (median >28 days); the pre-planned analyses at 6 months will provide additional information on the full effects of tocilizumab on clinical outcomes.

The RECOVERY results support the use of tocilizumab, but other IL-6 antagonists are available. Although the effects of sarilumab in REMAP-CAP were similar to tocilizumab, only 48 participants received sarilumab.⁸ Two larger trials of sarilumab have completed but have not reported any results (NCT044327388, NTC044315298). Publication of results from those trials is now essential to assess whether alternative IL-6 antagonists to tocilizumab are effective.

335 Guidelines on the use of IL-6 antagonists for patients with severe COVID-19 vary. For 336 example the US National Institutes for Health conclusion is that there are insufficient data 337 to recommend either for or against the use of tocilizumab or sarilumab, a view shared by 338 some commentators.^{19,20} By contrast, interim guidance in the NHS states that IL-6 339 antagonists should be considered for patients within 24 hours of starting non-invasive 340 respiratory support or invasive mechanical ventilation.²¹ Our results show that the benefits 341 of tocilizumab extend to a broader group of patients receiving oxygen with or without other 342 forms of respiratory support, and that those benefits include a reduction in the need for 343 invasive mechanical ventilation and other organ support such as renal replacement 344 therapy. Since complicating bacterial infections are infrequent in the early hospitalisation 345 period of COVID-19, this recognised concern in relation to the use of tocilizumab would 346 be lessened with earlier use.²²

Tocilizumab for COVID-19

347 Based upon the ISARIC4C database, approximately 49% of hospitalised COVID-19 348 patients in the UK would meet our inclusion criteria and hence would benefit from 349 tocilizumab (personal communication, ISARIC4C Investigators). CRP was chosen as the 350 biomarker for inflammation in this study since it is widely used and affordable worldwide, 351 it is correlated with serum IL-6 levels, and early clinical studies of COVID-19 had reported 352 it to be associated with severity and prognosis, with a value of >50 mg/L associated with 353 severe disease and a level of around 75 mg/L distinguishing fatal from non-fatal cases.²³⁻ 354 28 Whether hypoxic patients with a CRP <75 mg/L could benefit from tocilizumab is 355 unknown. Further work is also needed to consider the health economic benefits of 356 tocilizumab and related IL-6 inhibitors in terms of both patient outcomes and usage of 357 healthcare resources (duration of hospital stay, and frequency of invasive mechanical 358 ventilation and renal replacement therapy).

The RECOVERY trial has demonstrated that for patients hospitalized with severe COVID, treatment with tocilizumab reduces mortality, increases the chances of successful hospital discharge, and reduces the chances of requiring invasive mechanical ventilation. These benefits are additional to those previously reported for dexamethasone. These findings require an update to clinical guidelines and efforts to increase the global availability and affordability of tocilizumab.

365

Tocilizumab for COVID-19

366 **Contributors**

367 This manuscript was initially drafted by the PWH and MJL, further developed by the 368 Writing Committee, and approved by all members of the trial steering committee. PWH 369 and MJL vouch for the data and analyses, and for the fidelity of this report to the study 370 protocol and data analysis plan. PWH, MM, JKB, LCC, SNF, TJ, KJ, WSL, AM, KR, EJ, 371 RH, and MJL designed the trial and study protocol, MM, AR, G P-A, CB, RS, ICT, VJ, AA. 372 RPT, DC, MS, RS, BR, RH, the Data Linkage team at the RECOVERY Coordinating 373 Centre, Health Records, and Local Clinical Centre staff listed in the appendix collected 374 the data. ES, NS, and JRE verified the data and did the statistical analysis. All authors 375 contributed to data interpretation and critical review and revision of the manuscript. PWH 376 and MJL had access to the study data and had final responsibility for the decision to 377 submit for publication.

378 Writing Committee (on behalf of the RECOVERY Collaborative Group):

379 Professor Peter W Horby PhD FRCP,^{a,*} Mark Campbell FRCPath,^{b,c,*} Natalie Staplin PhD,^{b,d,*} Enti Spata,^{b,d,*} Professor Jonathan R Emberson PhD,^{b,d} Guilherme Pessoa-380 Amorim MD,^{b,e} Leon Peto PhD,^{a,c} Professor Christopher Brightling FRCP,^f Rahuldeb 381 382 Sarkar MPH.^{9,h} Koshy Thomas,ⁱ Vandana Jeebun,^j Abdul Ashish MD.^k Redmond P Tully FRCA,¹ David Chadwick PhD,^m Muhammed Muhammad Sharafat FRCA,ⁿ Richard 383 384 Stewart,^o Banu Rudran MRCP,^p J Kenneth Baillie MD PhD,^q Professor Maya H Buch PhD FRCP,^r Professor Lucy C Chappell PhD,^s Professor Jeremy N Day PhD FRCP,^{a,t} 385 386 Professor Saul N Faust PhD FRCPCH,^u Professor Thomas Jaki PhD,^{v,w} Katie Jeffery 387 PhD FRCP FRCPath,^c Professor Edmund Juszczak MSc,^x Professor Wei Shen Lim

Tocilizumab for COVID-19

- 388 FRCP,^{x,y} Professor Alan Montgomery PhD,^x Professor Andrew Mumford PhD,^z Kathryn
- 389 Rowan PhD,^A Professor Guy Thwaites PhD FRCP,^{a,t} Marion Mafham MD,^{b,†} Professor
- 390 Richard Haynes DM,^{b,d,†} Professor Martin J Landray PhD FRCP.^{b,d,e,†}

391

- ^a Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
- ³⁹³ ^bNuffield Department of Population Health, University of Oxford, Oxford, United
- 394 Kingdom
- ³⁹⁵ ^c Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
- ³⁹⁶ ^d MRC Population Health Research Unit, University of Oxford, Oxford, United Kingdom
- ⁹⁷ ^e NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS
- 398 Foundation Trust, Oxford, United Kingdom
- ³⁹⁹ ^f Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of
- 400 Leicester, Leicester, United Kingdom
- 401 ⁹ Medway Foundation NHS Trust, Gillingham, United Kingdom
- 402 ^h King's College London, London, United Kingdom
- ⁴⁰³ ⁱ Basildon and Thurrock Hospitals NHS Foundation Trust, Basildon, United Kingdom
- 404 ^j Department of Respiratory Medicine, North Tees & Hartlepool NHS Foundation Trust,
- 405 Stockton-on-Tees, United Kingdom

Tocilizumab for COVID-19

406	^k Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom
407	¹ Royal Oldham Hospital, Northern Care Alliance, Oldham, United Kingdom
408	^m Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United
409	Kingdom
410	ⁿ North West Anglia NHS Foundation Trust, Peterborough, United Kingdom
411	^o Milton Keynes University Hospital, Milton Keynes, United Kingdom
412	^p Luton & Dunstable University Hospital, Luton, United Kingdom
413	^q Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom
414	^r Centre for Musculoskeletal Research, University of Manchester, Manchester, and
415	NIHR Manchester Biomedical Research Centre, United Kingdom.
416	^s School of Life Course Sciences, King's College London, London, United Kingdom
417	^t Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam
418	^u NIHR Southampton Clinical Research Facility and Biomedical Research Centre,
419	University Hospital Southampton NHS Foundation Trust and University of Southampton
420	Southampton, United Kingdom
421	^v Department of Mathematics and Statistics, Lancaster University, Lancaster, United
422	Kingdom
423	^w MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom

Tocilizumab for COVID-19

- 424 × School of Medicine, University of Nottingham, Nottingham, United Kingdom
- 425 ^y Respiratory Medicine Department, Nottingham University Hospitals NHS Trust,
- 426 Nottingham, United Kingdom
- 427 ^z School of Cellular and Molecular Medicine, University of Bristol, Bristol, United
- 428 kingdom
- 429 ^A Intensive Care National Audit & Research Centre, London, United Kingdom
- 430 *,[†] equal contribution

431 Data Monitoring Committee

- 432 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo, Ian
- 433 Roberts (until December 2020), M Munavvar (since January 2021), Janet Wittes.

434 **Declaration of interests**

The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry (see <u>https://www.ndph.ox.ac.uk/files/about/ndph-independence-</u> <u>of-research-policy-jun-20.pdf</u>).

442 Data sharing

Tocilizumab for COVID-19

443 The protocol, consent form, statistical analysis plan, definition & derivation of clinical 444 characteristics & outcomes, training materials, regulatory documents, and other relevant 445 study materials are available online at www.recoverytrial.net. As described in the protocol, 446 the trial steering committee will facilitate the use of the study data and approval will not 447 be unreasonably withheld. Deidentified participant data will be made available to bona 448 fide researchers registered with an appropriate institution within 3 months of publication. 449 However, the steering committee will need to be satisfied that any proposed publication 450 is of high quality, honours the commitments made to the study participants in the consent 451 documentation and ethical approvals, and is compliant with relevant legal and regulatory 452 requirements (e.g. relating to data protection and privacy). The steering committee will 453 have the right to review and comment on any draft manuscripts prior to publication. Data 454 will be made available in line with the policy and procedures described at: 455 https://www.ndph.ox.ac.uk/data-access. Those wishing to request access should 456 complete the form at 457 https://www.ndph.ox.ac.uk/files/about/data access enquiry form 13 6 2019.docx

458 and e-mailed to: <u>data.access@ndph.ox.ac.uk</u>

459

460 Acknowledgements

Above all, we would like to thank the thousands of patients who participated in this study. We would also like to thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at 176 NHS hospital organisations across the whole of the UK, supported by staff at the National Institute of Health Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, Department of Health

Tocilizumab for COVID-19

& Social Care, the Intensive Care National Audit & Research Centre, Public Health
Scotland, National Records Service of Scotland, the Secure Anonymised Information
Linkage (SAIL) at University of Swansea, and the NHS in England, Scotland, Wales and
Northern Ireland.

470 The RECOVERY trial is supported by a grant to the University of Oxford from UK 471 Research and Innovation/NIHR (Grant reference: MC_PC_19056) and by core funding 472 provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda 473 Gates Foundation, the Department for International Development, Health Data Research 474 UK, the Medical Research Council Population Health Research Unit, the NIHR Health 475 Protection Research Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials 476 Unit Support Funding. TJ is supported by a grant from UK Medical Research Council 477 (MC UU 0002/14) and an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). 478 WSL is supported by core funding provided by NIHR Nottingham Biomedical Research 479 Centre. Abbvie contributed some supplies of lopinavir-ritonavir for use in this study. 480 Roche Products Ltd supported the trial through the provision of tocilizumab. REGEN-481 COV2 was provided for this study by Regeneron.

The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research, the Department of Health and Social Care, or Roche Products Limited.

485

Tocilizumab for COVID-19

486 **References**

487 1. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus
488 disease 2019: a model-based analysis. *Lancet Infect Dis* 2020; **20**(6): 669-77.

2. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in
hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:
prospective observational cohort study. *Bmj* 2020; **369**: m1985.

492 3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99
493 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
494 *Lancet* 2020.

495 4. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine 496 signature predicts COVID-19 severity and survival. *Nat Med* 2020; **26**(10): 1636-43.

497 5. Dorward DA, Russell CD, Um IH, et al. Tissue-Specific Immunopathology in Fatal 498 COVID-19. *Am J Respir Crit Care Med* 2021; **203**(2): 192-201.

499 6. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients 500 with Covid-19 - Preliminary Report. *N Engl J Med* 2020.

7. WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group, Sterne
 JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids
 and Mortality Among Critically III Patients With COVID-19: A Meta-analysis. *JAMA* 2020;
 324(13): 1330-41.

Sondon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in
 Critically III Patients with Covid-19 – Preliminary report. *medRxiv* 2021:
 2021.01.07.21249390.

508 9. Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical 509 outcomes at 15 days in patients with severe or critical coronavirus disease 2019: 510 randomised controlled trial. *BMJ* 2021; **372**: n84.

511 10. Rosas I, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients With 512 COVID-19 Pneumonia. *medRxiv* 2020: 2020.08.27.20183442.

513 11. Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs Usual Care in
514 Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A
515 Randomized Clinical Trial. *JAMA Intern Med* 2021; **181**(1): 32-40.

516 12. Salvarani C, Dolci G, Massari M, et al. Effect of Tocilizumab vs Standard Care on
517 Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized
518 Clinical Trial. JAMA Intern Med 2021; 181(1): 24-31.

519 13. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients
520 Hospitalized with Covid-19. *N Engl J Med* 2020; **383**(24): 2333-44.

Tocilizumab for COVID-19

521 14. Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-522 19 Pneumonia. *N Engl J Med* 2021; **384**(1): 20-30.

523 15. Recovery Collaborative Group, Horby P, Mafham M, et al. Effect of
524 Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med* 2020;
525 **383**(21): 2030-40.

16. Recovery Collaborative Group. Azithromycin in patients admitted to hospital with
 COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* 2021.

529 17. Recovery Collaborative Group, Horby PW, Mafham M, et al. Lopinavir-ritonavir in 530 patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, 531 open-label, platform trial. *Lancet* 2020; **396**(10259): 1345-52.

- 532 18. Sterne JAC, Diaz J, Villar J, et al. Corticosteroid therapy for critically ill patients
- 533 with COVID-19: A structured summary of a study protocol for a prospective meta-534 analysis of randomized trials. *Trials* 2020; **21**(1): 734.

535 19. National Institutes of Health. The COVID-19 Treatment Guidelines Panel's
536 Statement on the Use of Tocilizumab (and Other Interleukin-6 Inhibitors) for the
537 Treatment of COVID-19. 2021.

- 538 <u>https://www.covid19treatmentguidelines.nih.gov/statement-on-tocilizumab/</u> (accessed
 539 10/02/2021.
- 540 20. McCreary EK, Meyer NJ. Covid-19 controversies: the tocilizumab chapter. *BMJ* 541 2021; **372**: n244.
- 542 21. MHRA. Interleukin-6 inhibitors (tocilizumab and sarilumab) for critically ill patients 543 with COVID-19 pneumonia (adults). 2021.
- 544 <u>https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103138</u>
 545 (accessed 10/02/2021.
- 546 22. Baskaran V, Lawrence H, Lansbury L, et al. Co-infection in critically ill patients 547 with COVID-19: An observational cohort study from England. *medRxiv* 2020:
- 548 2020.10.27.20219097.
- 549 23. Escadafal C, Incardona S, Fernandez-Carballo BL, Dittrich S. The good and the 550 bad: using C reactive protein to distinguish bacterial from non-bacterial infection among 551 febrile patients in low-resource settings. *BMJ Glob Health* 2020; **5**(5).
- 552 24. Oberhoffer M, Karzai W, Meier-Hellmann A, Bogel D, Fassbinder J, Reinhart K.
 553 Sensitivity and specificity of various markers of inflammation for the prediction of tumor
 554 necrosis factor-alpha and interleukin-6 in patients with sepsis. *Crit Care Med* 1999;
 555 27(9): 1814-8.
- 556 25. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 557 2019 in China. *N Engl J Med* 2020; **382**(18): 1708-20.

Tocilizumab for COVID-19

558 26. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With 559 Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis* 2020; **71**(15): 762-8.

560 27. Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients:

561 Characteristics and prognostic factors based on 4-week follow-up. *J Infect* 2020; **80**(6):
562 639-45.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to
COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020.

566

Tocilizumab for COVID-19

568	Figures
569	
570	Figure 1: Trial profile - Flow of participants through the RECOVERY trial
571	
572	Figure 2: Effect of allocation to tocilizumab on (a) 28-day mortality and (b)
573	discharge from hospital alive within 28 days of randomisation
574	
575	Figure 3: Effect of allocation to tocilizumab on 28-day mortality by pre-specified
576	characteristics at randomisation
577	
578	Figure 4: Meta-analysis of mortality in randomised controlled trials of tocilizumab
579	in patients hospitalised with COVID-19
580	

Tocilizumab for COVID-19

581 **Table 1: Baseline characteristics by randomised allocation**

	Tocilizumab (n=2022)	Usual care (n=2094)
Maan (SD) Age yeers	62 2 (12 7)	62.0 (12.6)
Mean (SD) Age, years ≥18 to <70	63.3 (13.7)	63.9 (13.6)
	1332 (66%)	1354 (65%)
≥70 to <80	477 (24%)	480 (23%)
≥80	213 (11%)	260 (12%)
Sex		
Male	1335 (66%)	1437 (69%)
Female*	687 (34%)	657 (31%)
Ethnicity		
White	1356 (67%)	1426 (68%)
Black, Asian, or Minority Ethnic	341 (17%)	357 (17%)
Unknown	325 (16%)	311 (15%)
Number of days since symptom onset	9 (7-13)	10 (7-14)
Number of days since hospitalisation	2 (1-5)	2 (1-5)
Oxygen saturation, %	94 (92-96)	94 (91-95)
Respiratory support at second randomisation		
No ventilator support†	935 (46%)	933 (45%)
Non-invasive ventilation‡	819 (41%)	867 (41%)
Invasive mechanical ventilation§	268 (13%)	294 (14%)
Biochemistry at second randomisation		
Latest C-reactive protein, mg/L	143 (107-203)	144 (106-205)
Ferritin, ng/mL	947 (497-1599)	944 (507-1533)
Creatinine, umol/L	77 (62-98)	77 (62-100)
Previous diseases		
Diabetes	569 (28%)	600 (29%)
Heart disease	435 (22%)	497 (24%)
Chronic lung disease	473 (23%)	484 (23%)
Tuberculosis	3 (<1%)	5 (<1%)
HIV	7 (<1%)	8 (<1%)
Severe liver disease¶	14 (<1%)	10 (<1%)
Severe kidney impairment	118 (6%)	99 (5%)
Any of the above	1100 (54%)	1163 (56%)
SARS-Cov-2 test result		
Positive	1891 (94%)	1967 (94%)
Negative	68 (3%)	66 (3%)
Test result not yet known	63 (3%)	61 (3%)
First randomisation\$		
Number of days since first randomisation	0 (0-1)	0 (0-1)

Tocilizumab for COVID-19

	Tocilizumab (n=2022)	Usual care (n=2094)
Part A allocation		
Usual care	839 (41%)	869 (41%)
Lopinavir/ritonavir	51 (3%)	64 (3%)
Dexamethasone	49 (2%)	45 (2%)
Hydroxychloroquine	37 (2%)	38 (2%)
Azithromycin	197 (10%)	177 (8%)
Use of systemic corticosteroids^		
Yes	1664 (82%)	1721 (82%)
No	357 (18%)	367 (18%)
Unknown	1 (<1%)	6 (<1%)
Data are mean (SD) $n(%)$ or median (IOP)	Information on cox	theight and SARS (

Data are mean (SD), n(%), or median (IQR). Information on sex, ethnicity, and SARS-CoV-2 test result were recorded on the main randomisation form when patients first entered the study. All other information was recorded on the second randomisation form (when patients were randomly assigned to tocilizumab vs. usual care alone). * includes 3 pregnant women. † Includes 9 patients not receiving any oxygen and 1859 patients receiving low-flow oxygen. ‡ includes patients receiving high-flow nasal oxygen, continuous positive airway pressure, or other non-invasive ventilation). § Includes patients receiving invasive mechanical ventilation or extra-corporeal membranous oxygenation. ¶ Defined as requiring ongoing specialist care. || Defined as estimated glomerular filtration rate <30 mL/min/1.73m² \$ 2631 and 1615 participants were randomised into parts B and C of the first randomisation respectively. Alnformation on use of corticosteroids was collected from 18 June 2020 onwards following announcement of the results of the dexamethasone comparison from the RECOVERY trial. Participants undergoing first randomisation prior to this date (and who were not allocated to dexamethasone) are assumed not to be receiving systemic corticosteroids.

582

584585 Table 2: Effect of allocation to tocilizumab on main study outcomes


	Treatment	allocation		
	Tocilizumab (n=2022)	Usual care (n=2094)	RR (95% CI)	p value
Primary outcome				
Total: 28-day mortality	596 (29%)	694 (33%)	0.86 (0.77-0.96)	0.0066
Secondary outcomes				
Median time to being discharged alive, days	20	>28		
Discharged alive from hospital within 28 days	1093 (54%)	990 (47%)	1.22 (1.12-1.34)	<0.0001
Receipt of invasive mechanical ventilation or death*	571/1754 (33%)	687/1800 (38%)	0.85 (0.78-0.93)	0.0005
Invasive mechanical ventilation	215/1754 (12%)	273/1800 (15%)	0.81 (0.68-0.95)	0.01
Death	471/1754 (27%)	552/1800 (31%)	0.88 (0.79-0.97)	0.01
Subsidiary clinical outcomes				
Receipt of ventilation ⁺	233/935 (25%)	242/933 (26%)	0.96 (0.82-1.12)	0.61
Non-invasive ventilation	222/935 (24%)	223/933 (24%)	0.99 (0.84-1.17)	0.94
Invasive mechanical ventilation	45/935 (5%)	63/933 (7%)	0.71 (0.49-1.03)	0.07
Successful cessation of invasive mechanical ventilation‡	91/268 (34%)	94/294 (32%)	1.07 (0.80-1.43)	0.64
Use of haemodialysis or haemofiltration§	103/2003 (5%)	142/2075 (7%)	0.75 (0.59-0.96)	0.02

Data are n(%), n/N (%), or median (interquartile range). RR=rate ratio for the outcomes of 28-day mortality, hospital discharge and successful cessation of invasive mechanical ventilation, and risk ratio for other outcomes. * Analyses include only those on no ventilator support or non-invasive ventilation at second randomisation. † Analyses include only those on no ventilator support at second randomisation. ‡ Analyses restricted to those on invasive mechanical ventilation at second randomisation. § Analyses exclude those on haemodialysis or haemofiltration at second randomisation.


586

Figure 1: Trial profile – Flow of participants through the RECOVERY trial

medRxiv preprint doi: https://doi.org/10.1101/2021.02.11.21249258; this version posted February 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



ITT=intention to treat. *Number of adult patients recruited at a site activated for the tocilizumab comparison. †The first randomisation comprised up to 3 factorial elements such that an eligible patient could be entered into between 1 and 3 randomised comparisons, depending on the then current protocol, the patients suitability for particular treatments, and the availability of the treatment at the site. ‡ 1602/2022 (79%) patients of those allocated to tocilizumab and 1664/2094 (79%) of those allocated to usual care had a completed follow–up form at time of analysis.






Figure 3: Effect of allocation to tocilizumab on 28–day mortality by baseline characteristics

	Tocilizumab	Usual care		RR (95	% CI)
Age, years (χ_1^2 =0.1; p=0.80)					
<70	256/1332 (19%)	289/1354 (21%)		- 0.88 (0.74-	-1.04)
≥70 <80	206/477 (43%)	234/480 (49%)		0.84 (0.69-	-1.01)
≥80	134/213 (63%)	171/260 (66%)			-1.17)
Sex (χ ₁ ² =2.2; p=0.14)					
Men	400/1335 (30%)	504/1437 (35%)	-8-	0.81 (0.71-	-0.93)
Women	196/687 (29%)	190/657 (29%)	•	0.98 (0.80-	-1.20)
Ethnicity (χ ₁ ² =0.3; p=0.56)					
White	429/1356 (32%)	519/1426 (36%)		0.83 (0.73-	-0.95)
Black, Asian, or Minority Ethnic	98/341 (29%)	110/357 (31%)		— 0.91 (0.69-	-1.20)
Unknown	69/325 (21%)	65/311 (21%)		1.00 (0.71-	-1.41)
Days since symptom onset ()	ζ² =0.6; p=0.46)				
≤7	210/668 (31%)	245/660 (37%)		0.81 (0.67-	-0.97)
>7	386/1354 (29%)	449/1433 (31%)		0.88 (0.77-	-1.01)
Respiratory support at rando)=0.52)			
No ventilator support*	175/935 (19%)	202/933 (22%)		- 0.84 (0.69-	-1.03)
Non-invasive ventilation ⁺	296/819 (36%)	350/867 (40%)		0.86 (0.74-	-1.01)
Invasive mechanical ventilation	± 125/268 (47%)	142/294 (48%)		0.94 (0.73-	-1.19)
Use of corticosteroids\$ (χ_1^2 =7	.1; p=0.01)				
Yes	457/1664 (27%)	565/1721 (33%)		0.80 (0.70-	,
No	139/357 (39%)	127/367 (35%)		—— 1.16 (0.91-	-1.48)
Unknown	0/1 (0%)	2/6 (33%)			
All participants	596/2022 (29%)	694/2094 (33%)	\diamond	0.86 (0.77- p=0	-0.96) .0066
			0.5 0.75 1	1.5 2	
			Tocilizumab better	Usual care better	

Subgroup-specific rate ratio estimates are represented by squares (with areas of the squares proportional to the amount of statistical information) and the lines through them correspond to the 95% CIs. The ethnicity and days since onset subgroups exclude those with missing data, but these patients are included in the overall summary diamond. * Includes 9 patients not receiving any oxygen and 1859 patients receiving simple oxygen only. † Includes patients receiving high-flow nasal oxygen, continuous positive airway pressure ventilation, other non-invasive ventilation. ‡ Includes patients receiving invasive mechanical ventilation and extra-corporeal membranous oxygenation. \$ Information on use of corticosteroids was collected from 18 June 2020 onwards following announcement of the results of the dexamethasone comparison from the RECOVERY trial. Participants undergoing first randomisation prior to this date (and who were not allocated to dexamethasone) are assumed not to be receiving systemic corticosteroids.

Figure 4: Tocilizumab vs usual care in patients hospitalised with COVID – Meta–analysis of mortality in RECOVERY and other trials

	Deaths / Patients randomised (%)		Deaths / Patients randomised (%) Observed-Expected		-Expected			
	Tocilizumab	Usual care	(O-E)*	Var(O-E)	Ratio of death ra	ates, RR (95% CI)		
	7/04 (40.0)							
COR-IMUNO TOCI	7/64 (10.9)	8/67 (11.9)	-0.3	3.3		0.91 (0.31–2.65)		
RCT-TCZ-COVID-19	2/60 (3.3)	1/66 (1.5)	0.6	0.7	\leftarrow	2.17 (0.22–21.3)		
BACC Bay	9/161 (5.6)	(3/82) x2† (3.7)	1.0	2.6		1.51 (0.44–5.13)		
COVACTA	58/294 (19.7)	(28/144) x2† (19.4)	0.3	15.3	_	1.02 (0.62–1.68)		
EMPACTA	26/249 (10.4)	(11/128) x2† (8.6)	1.6	7.5		1.23 (0.60–2.52)		
REMAP-CAP	98/353 (27.8)	142/402 (35.3)	-14.2	40.8	e	0.71 (0.52–0.96)		
TOCIBRAS	14/65 (21.5)	6/64 (9.4)	3.9	4.3	\longrightarrow	2.51 (0.97–6.50)		
Subtotal: 7 trials	214/1246 (17.2)	241/1307 (18.4)	-7.2	74.5	\diamond	0.91 (0.72–1.14)		
RECOVERY	596/2022 (29.5)	694/2094 (33.1)	-48.2	316.0		0.86 (0.77–0.96)		
All trials	810/3268 (24.8)	935/3401 (27.5)	-55.4	390.5	\diamond	0.87 (0.79–0.96) p=0.005		
Heterogeneity between RECOVERY and previous trials: $\chi^2_1\!\!=\!\!0.2$						μ=0.005		
				0.2				
					Tocilizumab Tocilizumab better worse			

* Log-rank O-E for RECOVERY, O-E from 2x2 tables for the other trials. RR is calculated by taking In RR to be (O-E)/V with Normal variance 1/V. Subtotals or totals of (O-E) and of V yield inverse-variance-weighted averages of the In RR values.

† For balance, controls in the 2:1 studies count twice in the control totals and subtotals.